. 2017 Jan 6;15(2):237–248. doi: 10.1007/s40258-016-0301-y

Table 2.

Baseline values of patients assigned to the IDegLira treatment arm used for the cost-effectiveness analysis from DUAL™ II (NN9068-3912) [20]

Demographics and risk factors	Mean (standard deviation)
Age at presentation (years)	57.2 (9.7)
Duration of diabetes (years)	10.6 (6.5)
HbA_1c, %	8.8 (0.7)
SBP (mmHg)	132.4 (15.1)
TC (mmol/l)^a	4.67 (1.21)
LDL-C (mmol/l)^a	2.58 (0.96)
HDL-C (mmol/l)^a	1.16 (0.31)
Triglycerides (mmol/l)^a	2.18 (2.10)
BMI (kg/m²)	33.7 (5.7)

BMI body mass index, HbA _1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, IDegLira insulin degludec liraglutide, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, SBP systolic blood pressure

^aCholesterol was converted from mg/dL to mmol/L using the formula [mmol/l = (mg/dl)/39]. Triglycerides were converted from mg/dL to mmol/L using the formula [mmol/l = (mg/dl)/89]